Notice for emicizumab (Roche Products Pty Limited)
Active ingredients
emicizumab
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Injection solution
Indication
For routine prophylaxis in patients with haemophilia A (congenital factor Vlll deficiency)
Registration date